Results 301 to 310 of about 2,014,598 (359)
Conversion surgery for HCC. ABSTRACT Background Since 2013, we have performed conversion surgery after hepatic arterial infusion chemotherapy (HAIC) for initially unresectable locally advanced hepatocellular carcinoma (LA‐HCC). Methods Between 2013 and 2021, we assessed the surgical and oncological outcomes and pathological findings of patients with LA‐
Yuichi Goto+9 more
wiley +1 more source
Our aim was to compare the outcomes of preoperative chemotherapy with postoperative chemotherapy in patients with resectable colorectal liver metastases treated with CAPOX‐Bev. We demonstrated that both preoperative and postoperative CAPOX‐Bev were safely administered, and preoperative chemotherapy showed a numerically higher treatment compliance rate ...
Yuji Takakura+15 more
wiley +1 more source
This multi‐institutional, randomized, phase II trial aimed to investigate the long‐term survival outcomes of two versus three courses of DCF for locally advanced esophageal squamous cell carcinoma (ESCC). The 5‐year overall survival and progression‐free survival rates for the three and two course groups were 70.7% vs. 63.8% (hazard ratio (HR) = 0.91, p
Takahito Sugase+19 more
wiley +1 more source
Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer
ABSTRACT Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic ...
Katsutoshi Shoda+3 more
wiley +1 more source
Cuban health diplomacy: Focused on international cooperation. A comment on Chattu et al.
Romeu B.
europepmc +1 more source
ABSTRACT Background Neoadjuvant chemotherapy (NAC) has been extensively developed for locally advanced gastric cancer (GC). In Asia, S‐1‐based regimens, such as docetaxel, oxaliplatin, and S‐1 (DOS) and S‐1 and oxaliplatin (SOX), are expected to become the standard of care.
Kota Kawabata+9 more
wiley +1 more source
ABSTRACT Aims This study aimed to compare the clinicopathological features and short‐term outcomes of endoscopic submucosal dissection (ESD) and laparoscopic and endoscopic cooperative surgery (LECS) for superficial duodenal epithelial tumors (SDETs) and investigate the risk factors for severe adverse events (AEs).
Takuo Takehana+20 more
wiley +1 more source
The GLIM criteria are effective prognostic predictors in patients with resectable PDAC undergoing upfront surgery. Preoperative nutritional assessment using these criteria may contribute to determining treatment plans for resectable PDAC. ABSTRACT Aim Regarding the resectability of pancreatic adenocarcinoma (PDAC), not only anatomical factors but also ...
Takuya Mizumoto+9 more
wiley +1 more source